Number of people in the study with each immune-mediated disease and percentage of females
| Exposure cohort (ICD code*) | ORLS1 | ORLS2 | England |
| Total (% female) | Total (% female) | Total (% female) | |
| Addison's disease (E27.1) | 567 (59) | 570 (61) | 9291 (60) |
| Ankylosing spondylitis (M45) | 1044 (31) | 967 (29) | 20 569 (29) |
| Autoimmune haemolytic anaemia (D59.1) | 450 (55) | 351 (58) | 6806 (55) |
| Chronic active hepatitis (K73.2) | 438 (64) | 208 (67) | 4197 (71) |
| Crohn's disease (K50) | 4749 (59) | 5395 (57) | 102 388 (56) |
| Dermatomyositis, polymyositis (M33) | 334 (63) | 216 (65) | 5223 (63) |
| Diabetes mellitus under 30 years (E10–E14) | 5485 (48) | 4052 (49) | 68 768 (48) |
| Idiopathic thrombocytopaenia purpura (D69.3) | 874 (53) | 1106 (55) | 22 696 (55) |
| Multiple sclerosis (G35) | 4225 (66) | 3699 (68) | 69 840 (69) |
| Myasthenia gravis (G70.0) | 392 (62) | 396 (57) | 8638 (51) |
| Myxoedema (E03.8–E03.9) | 7368 (82) | 23 064 (81) | 597 057 (82) |
| Pemphigus, pemphigoid (L10, L12) | 564 (58) | 479 (57) | 10 672 (57) |
| Pernicious anaemia (D51.0) | 3885 (65) | 1422 (70) | 45 111 (69) |
| Polyarteritis nodosa (M30.0) | 298 (43) | 84 (38) | 1839 (44) |
| Primary biliary cirrhosis (K74.3) | 380 (79) | 355 (83) | 8363 (85) |
| Psoriasis (L40) | 4194 (51) | 3258 (48) | 79 643 (48) |
| Rheumatoid arthritis (M05–M06) | 15 114 (73) | 10 860 (72) | 247 414 (71) |
| Scleroderma (M34) | 427 (79) | 481 (84) | 9308 (82) |
| Sjogren's syndrome (M35.0) | 191 (88) | 443 (89) | 12 002 (88) |
| Systemic lupus erythematosus (M32.1–M32.9) | 712 (85) | 923 (87) | 20 005 (86) |
| Thyrotoxicosis (E05) | 5678 (81) | 4436 (78) | 88 553 (79) |
| Ulcerative colitis (K51) | 6525 (50) | 7779 (49) | 141 976 (49) |
↵* International Classification of Diseases (ICD) 10 codes for each immune-mediated disease (equivalent codes were used for cases coded in ICD revisions 7, 8 and 9).